Table 1.
Cardiotoxicity of monoclonal antibodies (MoAbs) in hematology.
| MoAb | Target | Indications | Cardiotoxicity |
|---|---|---|---|
| Rituximab | CD20 | NHL CLL | IRRs |
| Hypertension (6–12%) | |||
| Transient hypotension (10%) | |||
| SVT, AF | |||
| Takotsubo * | |||
| CAVB *, ST *, SB *, PVC *, VT *, QTc/TdP *, SCD * | |||
| Obinutuzumab | CD20 | CLL/FL | IRRs, SCD *, HF * |
| Ofatumumab | CD20 | CLL | IRRs |
| Hypertension/hypotension | |||
| Tachycardia | |||
| AF *, HF *, MI *, pericarditis * | |||
| Daratumumab | CD38 | MM | IRRs |
| Hypertension | |||
| AF | |||
| SCD * | |||
| Isatuximab | CD38 | MM | IRRs |
| AF | |||
| Elotuzumab | SLAMF7 | MM | IRRs |
| DVT | |||
| Brentuximab vedotin | CD30 | HL | ST (6%) |
| Pericardial effusion (3%) | |||
| CHF *, MI * | |||
| Nivolumab | PD-1 | HL | Myocarditis |
| Pericardial diseases | |||
| Stress cardiomyopathy | |||
| VT | |||
| CAVB *, SCD * | |||
| Pembrolizumab | PD-1 | HL | Myocarditis |
| Pericardial diseases | |||
| Stress cardiomyopathy | |||
| ST *, AF *, PVC *, VT *, SCD * | |||
| Gemtuzumab ozogamicin | CD33 | AML | VOD (2%) |
| Tachycardia, ST, SVT (13%) | |||
| Hypertension (17.3%) | |||
| Blinatumomab | CD19/CD3 | R/R Ph-ALL | Tachycardia |
| HF * | |||
| Belantamab mafodotin | BCMA | MM | Not reported |
| Inotuzumab ozogamicin | CD22 | Ph+ ALL | VOD |
| QT/QTc | |||
| Moxetumomab pasudotox | CD22 | R/R HCL | HUS * |
| Pericardial/pleural effusion * | |||
| Hypertension/hypotension * | |||
| Tachycardia * | |||
| Tafasitamab | CD19 | DLBCL | Pulmonary embolism (4%) |
| AF (2%) | |||
| CHF (2%) | |||
| Polatuzumab vedotin | CD79a | DLBCL | Hypotension |
| Ravulizumab | C5a | PNH HUS | Hypertension/hypotension * |
| Eculizumab | C5a | PNH HUS | Hypertension |
| Tachycardia/Palpitation | |||
| Cardiomyopathy * | |||
| Hypotension * | |||
| Emapalumab | IFNγ | R/R HLH | Hypertension (41%) |
| Tachycardia (12%) | |||
| Bradycardia * | |||
| Siltuximab | IL-6 | Castleman disease | Hypertension |
| Peripheral edema (26%) |
Abbreviations. MoAb, monoclonal antibodies; NHL, non-Hodgkin lymphomas; CLL, chronic lymphocytic leukemia; IRRs, infusion-related reactions; SVT, supraventricular tachycardia; AF, atrial fibrillation; CAVB, complete atrioventricular block; ST, sinus tachycardia; SB, sinus bradycardia; PVC, premature ventricular contractions; VT, ventricular tachycardia; QT/QTc, QT interval prolongation; TdP, torsade de pointes; SCD, sudden cardiac death; FL, follicular lymphoma; HF, heart failure; MI, myocardial infarction; MM, multiple myeloma; DVT, deep vein thrombosis; HL, Hodgkin lymphoma; CHF, congestive heart failure; PD-1, programmed cell death protein 1; AML, acute myeloid leukemia; VOD, veno-occlusive disease; R/R, relapsed/refractory; Ph, Philadelphia chromosome; ALL, acute lymphoblastic leukemia; BCMA, B cell maturation antigen; HCL, hairy cell leukemia; HUS, hemolytic uremic syndrome; DLBCL, diffuse large B cell lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; IFNγ, interferon gamma; HLH, hemophagocytic lymphohistiocytosis; IL-6, interleukin-6. * Uncommon and rare cardiotoxicity (frequency <1% or case reports).